RESUMO
The results of preoperative use of oxyprogesterone caproate (OPC), Tamoxifen and their combination in 165 patients suffering from primary endometrial carcinoma are presented. It was shown that Tamoxifen was able to increase concentrations cytoplasmatic receptors to progesterone in the tumor. The incidence of specific hormonal pathomorphosis in the tissue of the tumor in patients who received a combination of OPC and Tamoxifen was significantly higher (80% of cases) as compared to the separate use of OPC (60%) or Tamoxifen (57%).
Assuntos
Hidroxiprogesteronas/uso terapêutico , Receptores de Estradiol/metabolismo , Receptores de Progesterona/metabolismo , Tamoxifeno/uso terapêutico , Neoplasias Uterinas/metabolismo , Caproato de 17 alfa-Hidroxiprogesterona , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Citoplasma/metabolismo , Estradiol/sangue , Feminino , Hormônio Foliculoestimulante/metabolismo , Humanos , Hidroxiprogesteronas/administração & dosagem , Hormônio Luteinizante/metabolismo , Pessoa de Meia-Idade , Tamoxifeno/administração & dosagem , Neoplasias Uterinas/tratamento farmacológico , Neoplasias Uterinas/patologia , Vagina/patologiaAssuntos
Envelhecimento , Glicemia/metabolismo , Metabolismo Energético , Ácidos Graxos/sangue , Hormônio do Crescimento/sangue , Sistema Hipotálamo-Hipofisário/metabolismo , Insulina/sangue , Adolescente , Adulto , Catecolaminas/metabolismo , Ritmo Circadiano , Emulsões Gordurosas Intravenosas/farmacologia , Feminino , Glucose/farmacologia , Homeostase , Humanos , Pessoa de Meia-IdadeRESUMO
It is shown that daily oral administration of 5--10 mg of an antidiabetic biguanide-phenformin (phenethyl-biguanide) for 2.5--5 months suppressed DMBA-induced mammary tumour development in rats considerably. Phenformin-treated rats revealed-a tendency towards a decrease in blood insulin level (radioimmunoassay). The obtained data are regarded as additional evidence for the proposed existence of the same metabolic background of diseases of compensation, i.e. adult-onset diabetes, artherosclerosis and cancer, and suggest studies on possible antitumour effect of phenformin in man.